Novo Integrated Sciences, Inc.

NasdaqCM:NVOS Stock Report

Market Cap: US$8.9m

Novo Integrated Sciences Past Earnings Performance

Past criteria checks 0/6

Novo Integrated Sciences's earnings have been declining at an average annual rate of -50.4%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been growing at an average rate of 7.4% per year.

Key information

-50.4%

Earnings growth rate

-34.7%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate7.4%
Return on equity-55.2%
Net Margin-88.5%
Last Earnings Update29 Feb 2024

Recent past performance updates

Recent updates

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump

Apr 18
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump

Novo Integrated Sciences prices 4M unit public offering at $.50/unit

Oct 14

Novo Integrated Sciences expects to report over fivefold increase in Q3 revenue

Jul 11

Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?

Nov 23
Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Aug 07
Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Mar 02
Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Revenue & Expenses Breakdown
Beta

How Novo Integrated Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:NVOS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
29 Feb 2414-12150
30 Nov 2313-14150
31 Aug 2313-13140
31 May 231-32140
28 Feb 2312-35150
30 Nov 2212-35160
31 Aug 2212-33140
31 May 2223-12120
28 Feb 2211-9100
30 Nov 2110-590
31 Aug 219-480
31 May 218-7100
28 Feb 217-690
30 Nov 207-680
31 Aug 208-570
31 May 208-140
29 Feb 2010-140
30 Nov 1910040
31 Aug 199040
31 May 199-140
28 Feb 199-140
30 Nov 189-250
31 Aug 189-250
31 May 189-250
28 Feb 189-250
30 Nov 178-140
31 Aug 178-130
31 May 178-130
28 Feb 177020
30 Nov 167020
31 Aug 167020
31 Aug 157-230

Quality Earnings: NVOS is currently unprofitable.

Growing Profit Margin: NVOS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NVOS is unprofitable, and losses have increased over the past 5 years at a rate of 50.4% per year.

Accelerating Growth: Unable to compare NVOS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NVOS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7.1%).


Return on Equity

High ROE: NVOS has a negative Return on Equity (-55.25%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.